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Risk factors for clinical outcomes of COVID‑19 pneumonia have not yet been well established in 
patients with underlying liver diseases. Our study aimed to describe the clinical characteristics and 
outcomes of COVID‑19 infection among patients with underlying liver diseases and determine the 
risk factors for severe COVID‑19 among them. In a retrospective analytical study, 1002 patients with 
confirmed COVID‑19 pneumonia were divided into two groups: patients with and without underlying 
liver diseases. The admission period was from 5 March to 14 May 2020. The prevalence of underlying 
conditions, Demographic data, clinical parameters, laboratory data, and participants’ outcomes were 
evaluated. Logistic regression was used to estimate the predictive factors. Eighty‑one (8%) of patients 
had underlying liver diseases. The frequencies of gastrointestinal symptoms such as diarrhea and 
vomiting were significantly higher among patients with liver diseases (48% vs. 25% and 46.1% vs. 30% 
respectively, both P < 0.05). Moreover, ALT and AST were significantly higher among patients with liver 
diseases (54.5 ± 45.6 vs. 37.1 ± 28.4, P = 0.013 and 41.4 ± 27.2 vs. 29.2 ± 24.3, P = 0.028, respectively). 
Additionally, the mortality rate was significantly high in patients with liver disease (12.4% vs. 7%, 
P = 0.018). We also observed that the parameters such as neutrophil to leukocyte ratio [Odds Ratio 
Adjusted  (ORAdj) 1.81, 95% CI 1.21–3.11, P = 0.011] and blood group A  (ORAdj 1.59, 95% CI 1.15–2.11, 
P = 0.001) were associated with progression of symptoms of COVID‑19. The presence of underlying 
liver diseases should be considered one of the poor prognostic factors for worse outcomes in patients 
with COVID‑19.
The novel coronavirus, called SARS-CoV-2, which causes severe acute respiratory syndrome (COVID-19), was 
first reported in China in December 2019 and spread quickly  worldwide1. Similar to the previous members of 
this family, COVID-19 commonly causes respiratory tract infection, which can be asymptomatic, mild, or severe. 
However, in some cases, it can cause a lethal condition. Although the mortality rate of COVID-19 is believed to 
be low, older adults and those with a chronic disease are at increased risk of severe symptoms, poorer prognosis, 
and even fatal  conditions1. Furthermore, multi-organ damages are common among infected patients due to an 
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inflammatory cascade induced by COVID-19. Heart failure, renal failure, acute respiratory distress syndrome 
(ARDS), liver damage, and shock can be the most important of these  complications2,3.
Liver injury, which is often seen among severe cases of COVID-194,5, is mostly accompanied by increased 
liver enzymes and  bilirubin6. Although some studies have proven that COVID-19 can cause liver injury, the 
exact effects of background liver diseases on clinical outcomes of COVID-19 infection are not clear. One study 
showed no correlation between liver diseases and increased risk of COVID-197. Moreover, the prognostic factors 
in COVID-19 patients with underlying liver diseases are not clear. Some studies have suggested that lab tests 
such as lymphopenia and high CRP levels are independently correlated with liver  injury8,9. Yet, more extensive 
studies are needed to define the possible risk factors in patients with underlying liver diseases for developing 
severe COVID-19.
Our study aimed to describe the clinical characteristics, laboratory data and epidemiologic factors in COVID-
19 patients with and without underlying liver disease and discuss the potential risk factors for developing severe 
symptoms in patients with underlying liver diseases.
Materials and methods
This Retrospective study was approved by the Research Ethics Committee of Baqiyatallah University of Medical 
Sciences, Tehran, Iran (IR.BMSU.REC) with number code IR.BMSU.REC. 1399. 186. We obtained the patients’ 
informed consent to be allowed to use their medical information. The methods were carried out in accordance 
with the relevant guidelines and regulations.
In this retrospective analytical study from 5 March to 4 May 2020, we evaluated the records of 1002 cases 
with COVID-19 pneumonia who were admitted to our centers (Baqiyatallah and Rasoul-e-Akram Hospitals) 
in Tehran, Iran. The diagnosis of COVID-19 for all subjects was confirmed using real-time PCR and CT-scan. 
Written consent for research purposes was taken from patients at the time of diagnosis. According to the National 
Health Commission (Trial Version 5)10 and the guideline for the diagnosis and treatment of COVID-19 infection, 
all patients with positive PCR test and imaging feature in favor of COVID-19 were considered as infected cases. 
Besides, at the beginning of the admission, patients with respiratory rate > 30 breaths/min,  SpO2 < 93% or  PaO2/
FiO2 ≤ 300 mmHg, were defined as severe and otherwise considered as mild cases.
The data collection checklist encompassed different characteristics such as demographic data including age, 
sex, educational level, smoking habits, trip history (in the last 2 weeks), and clinical features like initial symptoms, 
past medical history and comorbidities (e.g., hypertension, diabetes, cardiovascular diseases, and respiratory 
diseases), initial laboratory investigations including complete blood count, coagulation function, routine bio-
chemical, and liver function tests data. We also collected the CT-scan features for all participants. The outcomes 
were defined as death, readmission, and duration of hospitalization. The records of subjects with considerable 
lacking were excluded. Participants were divided into two groups; (1) cases with liver diseases such as cirrhosis, 
grade II or higher fatty liver, and viral hepatitis, (2) cases without liver disease. The diagnosis of any liver diseases 
was confirmed via patients’ previous documents.
Statistical analysis. The mean and standard deviation (SD) were conducted to describe continuous vari-
ables and qualitative data. The descriptive analysis was performed using frequencies. We used Kolmogorov–
Smirnov and Shapiro–Wilk normality tests, P–P plot, and histogram to evaluate our study data’s normality. For 
the continuous variables, a t-test was employed to analyze the mean difference in parametric and the Mann–
Whitney U test in the non-parametric condition. The Chi-squared test (χ2 test) was conducted for the classified 
variables. Logistic regression analysis was use to evaluate the risk factors for severe COVID-19. Variables with 
P < 0.10 in the univariate analysis test were entered into a multivariate logistic regression analysis with the back-
ward selection method. Two-tailed P-values < 0.05 were considered as statistically significant values. IBM SPSS 
Statistics 20.0 software (https ://www.ibm.com/analy tics/spss-stati stics -softw are) software was used to analyze 
the data.
Results
During the study period, 1002 patients with confirmed COVID-19 pneumonia were enrolled, among whom 
81 patients (8%) had underlying liver disease. The mean age in liver diseases and non-liver diseases groups was 
62.2 ± 14.9 and 58.5 ± 12.9 years, respectively. The male subjects were 56 (69%) in liver diseases and 609 (66.1%) 
in the non-liver diseases groups. There was no significant difference in age and sex between the two groups (both 
P-values > 0.05). Regarding the previous history of respiratory disease, no significant difference was observed for 
such a variable. The frequency of cases with severe symptoms was significantly higher in the liver diseases group 
(P-value = 0.011). Moreover, at the admission time, the frequency of patients with gastrointestinal complications 
such as diarrhea and vomiting were higher among the participants with liver diseases (P-value < 0.05). Table 1 
shows a summary of the baseline characteristics and clinical history of the participants.
Table 2 represents the laboratory and clinical features of the included cases. The presence of underlying liver 
diseases led to a higher mortality rate, which means poorer prognosis. The patients with underlying liver diseases 
significantly stayed longer at the hospital (94% vs. 68.7%, P = 0.021). During this period, the levels of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly higher in patients with known 
liver diseases (54.5 ± 45.6 vs. 37.1 ± 28.4, 41.4 ± 27.2 vs. 29.2 ± 24.3, both P-value < 0.05). Furthermore, the patients 
with liver diseases showed degrees of coagulopathy since the INR in this group was significantly higher than the 
other group (1.9 ± 0.18 vs. 1.02 ± 0.09; P-value = 0.001).
Risk factors of severe COVID‑19 among the cases with liver disease. We conducted an adjusted 
logistic regression analysis to control confounders or collinearity to assess the factors associated with severe 
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COVID-19 infection in patients with liver diseases. Variables with P-value < 0.10 in the univariate analysis test 
including age, the severity of COVID-19 taste sense, vomiting, diarrhea, blood group, leucocytes, neutrophils, 
lymphocytes, platelets, hemoglobin, albumin, ALT, AST, BS, INR, chest CT findings, hospital stay and death 
were entered into logistic regression analysis. As shown in Table 3, age ≥ 60 years, the higher level of neutrophil-
to-lymphocyte ratio (NLR), blood group A and presence of any other comorbidity were predictable risk factors 
for the severity of COVID-19 in cases with liver diseases. Notably, after performing the same model on the cases 
without liver diseases, it was revealed that older ages and any other comorbidity were associated with a higher 
risk of severe symptoms of COVID-19. However, unlike patients with liver diseases, blood group A showed a 
protective effect  (ORAdj 0.67, 95% CI 0.39–0.96, P-value = 0.001).
Discussion
This study showed that underlying liver diseases would lead to probable serious outcomes in COVID-19 patients. 
Our study showed that age ≥ 60 years, higher levels of NLR, blood group A and the presence of any other comor-
bidity were predictable risk factors for the severity of COVID-19 in the patients suffering from liver diseases. 
In contrast, in the non-liver diseases group, only two factors of age ≥ 60 years and the presence of any other 
comorbidity were associated with the severity of COVID-19. This is in line with the results of a meta-analysis 
conducted by Francesco et al.11. However, age ≥ 60 years was reported as a risk factor in both liver and non-liver 
diseases groups for the severity of COVID-19. It’s OR was higher in liver diseases than non-liver diseases group 
(1.29 vs. 1.09). It is probably due to more disruption of innate and adaptive immunity in patients with liver dis-
eases. Because such diseases interfere with the production of complements, antimicrobial peptides, and cytokines, 
moreover, the antigen presentation to the immune system will be disturbed in liver  diseases12.
Several comorbidities (e.g., hypertension, diabetes, cardiovascular diseases, and respiratory diseases) are 
associated with poorer outcomes in infected  individuals13. However, liver-related comorbidities were not com-
mon among the patients with COVID-19 pneumonia and their frequency was about 3%14. Although liver enzyme 
abnormality was common in patients, it barely resulted in a serious liver  injury4,5,13. This can imply that the liver 
is not a target organ for SARS-CoV-2. The very low expression of the ACE2 receptor in hepatocytes and bile 
duct  epithelium15,16 may explain the small influence of viral infection in the liver. Our study also revealed that 
patients with liver diseases are more susceptible to COVID-19 than cases without comorbidity. Based on our 
study results, the presence of any other comorbidity in both groups was significantly associated with the severity 
of COVID-19. However, the OR for this risk factor was higher in liver diseases than the non-liver diseases group 
(1.32 vs. 1.12). It can be justified by the synergistic interaction between liver diseases and comorbidities in this 
Table 1.  Baseline characteristics of study population. MI myocardial infarction, COPD chronic obstructive 
pulmonary disease, CVD cardiovascular disease.
Variable
Liver diseases Non-liver diseases
P-valueGroup (N: 81) (N: 921)
Age 62.2 ± 13.95 58.5 ± 12.9 0.41
Sex 0.72
Male 56 (69%) 609 (66.1%)
Female 25 (31%) 312 (33.9%)
Exposure history (in the last 2 weeks)
Contact with patients 45 (55.5%) 444 (48.2%) 0.45
Go hospital 52 (64.1%) 590 (64%) 0.68
Public transportation 23 (28.4%) 230 (25%) 0.77
Current smoker 6 (7.4%) 42 (4.5%) 0.33
Hypertension 26 (32.1%) 276 (29.9%) 0.57
Diabetes 21 (26%) 219 (23.8%) 0.38
CVD 16 (19.7%) 166 (17.9%) 0.59
MI 3 (3.7%) 25 (2.7%) 0.18
Lung Diseases and COPD 18 (22.2%) 149 (16.2%) 0.11
Asthma 5 (6.1%) 43 (4.7%) 0.23
Kidney Diseases 5 (6.1%) 66 (7.1%) 0.46
Cancer 2 (2.4%) 17 (1.8%) 0.33
Blood group
A 35 (43.2%) 258 (28%) 0.001
B 17 (20.9%) 231 (25%) 0.14
AB 8 (9.8%) 112 (12.3%) 0.26
O 21 (26.1%) 183 (34.7%) 0.048
Classification COVID-19 0.011
Mild 18 (22.2%) 553 (60%)
Severe 63 (77.8%) 368 (40%)
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Table 2.  Clinical characteristics and initial symptoms and laboratory indices among patients with and without 
liver diseases. PCR Polymerase chain reaction, ALT alanine aminotransferase, AST aspartate transaminase, BS 
blood sugar, INR international normalized ratio, CRP C-reactive protein.
Variable Normal range
Liver diseases Non-liver diseases
P-valueGroup (N: 81) (N: 921)
Fever N (%) 0.015
≥ 38.5 °C 35 (43.2%) 175 (19%)
< 38.5 °C 46 (56.8%) 746 (81%)
Cough N (%) 47 (58%) 552 (60%) 0.82
Chest pain N (%) 20 (25%) 221 (24%) 0.51
Dizziness N (%) 20 (25%) 313 (34%) 0.12
Headache N (%) 26 (32%) 275 (29.8%) 0.59
Weakness N (%) 47 (58%) 497 (54%) 0.42
Myalgia N (%) 49 (60%) 485 (53.3%) 0.33
Diarrhea N (%) 39 (48%) 230 (25%) 0.036
Vomiting N (%) 37 (46.1%) 276 (30%) 0.033
Test sense N (%) 13 (16%) 166 (18.1%) 0.31
Laboratory findings, median (IQR)
Leucocytes (× 109/L) 4–10 9.522 ± 7.64 6.2 ± 3.01 0.016
Neutrophils (× 109/L) 02–07 61.17 ± 0.82 4.4 ± 0.75 0.043
Lymphocytes (× 109/L) 0.8–4 2.4 ± 1.94 2.01 ± 1.22 0.077
Platelets (× 109/L) 125–450 162.2 ± 56.2 155.65 ± 72.2 0.066
Hemoglobin (g/L) 12-18 15.1 ± 1.5 14.6 ± 1.6 0.081
Hematocrit (%) 38–50.8 44.15 ± 3.9 43.2 ± 4.5 0.19
Blood biochemistry
Albumin (g/L) 40–55 45.5 ± 7.3 40.5 ± 6.1 0.031
ALT (U/L) 9–50 54.5 ± 45.6 37.1 ± 28.4 0.031
AST (U/L) 15–40 41.4 ± 27.2 29.2 ± 24.3 0.028
Total bilirubin (mmol/L) 0–26 10.2 ± 3.7 8.9 ± 4.3 0.15
Serum sodium (mmol/L) 137–147 136.6 ± 15.5 138.1 ± 18.9 0.55
Serum potassium (mmol/L) 3.5–5.3 3.55 ± 2.3 3.71 ± 2.6 0.48
BS(Mg/dL) 70–140 119.1 ± 24.3 111.2 ± 25.3 0.078
INR 0.85–1.15 1.9 ± 0.18 1.02 ± 0.09 0.001
CRP (mg/L)d 0–10 45.2 ± 32.1 39.2 ± 31.2 0.045
Chest CT findings N (%)
Mild conflict 7 (8.6%) 110 (12%) 0.059
Unilateral 11 (13.5%) 249 (27.1%) 0.001
Bilateral 32 (39.5%) 313 (34%) 0.22
Ground-glass opacity 31 (38.4%) 249 (26.9%) 0.042
Clinical outcome
Increased hospital stay > 7 days N (%) 76 (93.8%) 598 (65%) 0.021
Death N (%) 10 (12.4%) 65 (7%) 0.018
Readmission N (%) 8 (9.8%) 98 (10.6%) 0.42
Table 3.  Multivariate logistic regression of factors associated with progression of disease in patients with 
underlying liver diseases and without underlying liver diseases. ORAdj Odds ratio adjusted, 95% CI 95% 
confidence interval, NLR neutrophil-to-lymphocyte ratio.
Variable
Group
Liver diseases Non-liver diseases
ORAdj 95% CI P value ORAdj 95% CI P-value
Age ≥ 60 year 1.29 1.06–1.35 0.001 1.09 1.03–2.11 0.048
Comorbidities 1.32 1.09–3.12 0.011 1.12 1.03–3.55 0.023
Blood group (A) 1.59 1.15–2.11 0.001 0.67 0.39–0.96 0.001
Chest CT findings (unilateral) 0.42 0.12–0.76 0.023 0.72 0.41–1.58 0.068
NLR 1.81 1.21–3.11 0.011 1.02 0.66–2.97 0.28
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group. The liver diseases themselves could affect other parts like the circulatory system (enlarges blood vessels) 
as well as lung and kidney, hepatopulmonary and hepatorenal syndromes, for instance. On the other hand, the 
association of metabolic syndrome and glucose intolerance in fatty liver disease can significantly influence the 
heart. These findings could be more prominent in elders, explaining more OR for the severity of symptoms in 
the liver diseases group older than sixty and suffering from any other comorbidity. Moreover, the administration 
of hepatotoxic drugs could be the other coexisting  mechanism14. Although most patients with underlying liver 
diseases had mild infections, the frequency of severe outcomes was significantly higher among them. Therefore, 
the presence of abnormalities in the liver may accelerate the progression of the illness.
Patients with chronic liver diseases, such as cirrhosis, are vulnerable to infections because of their immuno-
compromised  state12,17. Besides, the SARS-CoV-2 virus damages the lymphocytes, especially T  cells18,19, which 
leads to impairment in a patient’s immune system function and makes them more susceptible to infections. 
Furthermore, a higher level of NLR may increase the risk of bacterial  infections20. A meta-analysis demonstrated 
that the increased level of NLR is associated with poorer outcomes in patients with COVID-1921. Consistent with 
the previous reports, we observed that this marker’s higher level is directly proportional to the severity of disease 
in the liver diseases group. However, no significant correlation was observed for NLR levels in patients with liver 
disease. This observation may indicate the high probability of bacterial superinfection among these populations.
The association of blood group type with several viral infections has been  proven9,22. The results of our study 
revealed that the patients with blood group A had a higher risk of COVID-19 progression. While in the non-liver 
diseases group, blood group A had a protective role. This finding is consistent with the previous studies in this 
respect. Zhao et al. showed that blood group A subjects are more likely to get COVID-19 pneumonia than the 
subjects with non-A blood  groups23. In an in vivo setting, Guillon et al. demonstrated that the human natural 
anti-A antibodies would prevent the interaction between the ACE2 receptor and SARS-CoV-2, offering protec-
tion for subjects who possess such  antibodies24.
Our study had some strengths and weak points. The main strong point of this study was a considerably large 
number of included participants with COVID-19 infection. The study’s main weakness was the small number of 
patients with liver diseases, which did not allow several analyses. Due to limited medical resources during this 
pandemic, patients with severe COVID-19 pneumonia were more likely to be hospitalized.
Conclusion
This study’s findings demonstrated that the presence of any chronic liver disease is associated with poorer out-
comes in a population with COVID-19.
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